Eli Lilly and Company $LLY Shares Bought by Forum Financial Management LP

Key Points

• Forum Financial Management LP increased its stake in Eli Lilly, boosting holdings by 5.2% to 8,805 shares worth approximately $6.86 million.
• Recent insider trading activity includes Director Gabrielle Sulzberger purchasing 117 shares and EVP Daniel Skovronsky acquiring 1,000 shares, reflecting confidence in the company's performance.
• In the latest quarter, Eli Lilly reported $6.31 EPS, exceeding analysts' expectations, with a year-over-year revenue increase of 37.6% to $15.56 billion.

Forum Financial Management LP raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,805 shares of the company's stock after purchasing an additional 437 shares during the quarter. Forum Financial Management LP's holdings in Eli Lilly and Company were worth $6,864,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Hobbs Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC lifted its holdings in Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Willner & Heller LLC boosted its position in Eli Lilly and Company by 1.5% during the 1st quarter. Willner & Heller LLC now owns 854 shares of the company's stock valued at $705,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Down 0.0%

Shares of LLY stock opened at $799.21 on Wednesday. The stock has a market cap of $756.42 billion, a PE ratio of 52.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The business's fifty day moving average is $759.77 and its 200-day moving average is $766.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the previous year, the firm posted $3.92 EPS. The company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Finally, Morgan Stanley lowered their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.